Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1904 1
1949 1
1950 1
1951 3
1952 1
1953 3
1954 4
1955 1
1958 2
1960 1
1962 2
1965 1
1967 2
1973 2
1974 2
1975 1
1978 2
1979 2
1984 1
1985 1
1986 1
1988 1
1990 2
1991 1
1992 2
1993 1
1994 2
1995 1
2000 4
2002 2
2004 1
2005 2
2007 2
2008 2
2010 1
2011 4
2012 3
2013 8
2014 11
2015 6
2016 19
2017 16
2018 4
2019 6
2020 7
2021 3
2022 9
2023 6
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Free PMC article. Clinical Trial.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. J Clin Oncol. 2025. PMID: 39591551 Free PMC article. Clinical Trial.
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P. Rannikko JH, et al. Among authors: graham dm. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. Cell Rep Med. 2023. PMID: 38056464 Free PMC article. Clinical Trial.
Lab Animal is turning 45.
Graham DM. Graham DM. Lab Anim (NY). 2016 Jan;45(1):3. doi: 10.1038/laban.914. Lab Anim (NY). 2016. PMID: 26684940 No abstract available.
Mechanotransduction and nuclear function.
Graham DM, Burridge K. Graham DM, et al. Curr Opin Cell Biol. 2016 Jun;40:98-105. doi: 10.1016/j.ceb.2016.03.006. Epub 2016 Mar 25. Curr Opin Cell Biol. 2016. PMID: 27018929 Free PMC article. Review.
Lipoproteins in atherosclerosis.
JONES HB, GOFMAN JW, LINDGREN FT, LYON TP, GRAHAM DM, STRISOWER B, NICHOLS AV. JONES HB, et al. Among authors: graham dm. Am J Med. 1951 Sep;11(3):358-80. doi: 10.1016/0002-9343(51)90171-4. Am J Med. 1951. PMID: 14877839 No abstract available.
Mechanotransduction: from the cell surface to the nucleus via RhoA.
Burridge K, Monaghan-Benson E, Graham DM. Burridge K, et al. Among authors: graham dm. Philos Trans R Soc Lond B Biol Sci. 2019 Aug 19;374(1779):20180229. doi: 10.1098/rstb.2018.0229. Epub 2019 Jul 1. Philos Trans R Soc Lond B Biol Sci. 2019. PMID: 31431179 Free PMC article. Review.
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Grivas P, Garralda E, Meric-Bernstam F, Mellinghoff IK, Goyal L, Harding JJ, Dees EC, Bahleda R, Azad NS, Karippot A, Kurzrock R, Tabernero J, Kononen J, Ng MCH, Mehta R, Uboha NV, Bigot F, Boni V, Bowyer SE, Breder V, Cervantes A, Chan N, Cleary JM, Dhawan M, Eefsen RL, Ewing J, Graham DM, Guren TK, Won Kim J, Koynov K, Oh DY, Redman R, Yen CJ, Spetzler D, Roubaudi-Fraschini MC, Nicolas-Metral V, Ait-Sarkouh R, Zanna C, Ennaji A, Pokorska-Bocci A, Flaherty KT. Grivas P, et al. Among authors: graham dm. Clin Cancer Res. 2024 Oct 15;30(20):4572-4583. doi: 10.1158/1078-0432.CCR-24-0012. Clin Cancer Res. 2024. PMID: 38771739 Free PMC article. Clinical Trial.
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I. Chung HC, et al. Among authors: graham dm. Cancer. 2024 Oct 1;130(19):3278-3288. doi: 10.1002/cncr.35387. Epub 2024 Jun 21. Cancer. 2024. PMID: 39031824 Free article. Clinical Trial.
Patient attrition in Molecular Tumour Boards: a systematic review.
Frost H, Graham DM, Carter L, O'Regan P, Landers D, Freitas A. Frost H, et al. Among authors: graham dm. Br J Cancer. 2022 Nov;127(8):1557-1564. doi: 10.1038/s41416-022-01922-3. Epub 2022 Aug 8. Br J Cancer. 2022. PMID: 35941175 Free PMC article.
164 results